Level B· Emerging clinical evidence with positive signalsRandomized Controlled TrialEurope PMC

Insulin sensitizing and anti-inflammatory effects of thiazolidinediones are heightened in obese patients

Esterson YB., Zhang K., Koppaka S., Kehlenbrink S., Kishore P., Raghavan P.

Randomized Controlled Trial on Type 2 Diabetes, Chronic Inflammation, published in J Investig Med (2013) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Randomized Controlled Trial
Journal
J Investig Med (2013)
Reported sample size
—
Source database
Europe PMC
PMID
24141239
PMCID
PMC3933072
DOI
10.2310/jim.0000000000000017
Citations
26

Abstract (original English)

Objective The American Diabetes Association has called for further research on how patients' demographics should determine drug choices for individuals with type 2 diabetes mellitus (T2DM). Here, using in-depth physiology studies, we investigate whether obese patients with T2DM are likely to benefit from thiazolidinediones, medications with a known adverse effect of weight gain. Materials and methods Eleven obese and 7 nonobese individuals with T2DM participated in this randomized, placebo-controlled, double-blind, crossover study. Each subject underwent a pair of "stepped" pancreatic clamp studies with subcutaneous adipose tissue biopsies after 21 days of pioglitazone (45 mg) or placebo. Results Obese subjects demonstrated significant decreases in insulin resistance and many adipose inflammatory parameters with pioglitazone relative to placebo. Specifically, significant improvements in glucose infusion rates, suppression of hepatic glucose production, and whole fat expression of certain inflammatory markers (IL-6, IL-1B, and inducible nitric oxide synthase) were observed in the obese subjects but not in the nonobese subjects. Additionally, adipose tissue from the obese subjects demonstrated reduced infiltration of macrophages, dendritic cells, and neutrophils as well as increased expression of factors associated with fat "browning" (peroxisome proliferator-activated receptor g

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence
HumansDiabetes Mellitus, Type 2Insulin ResistanceObesityThiazolidinedionesAnti-Inflammatory AgentsInflammation MediatorsHypoglycemic AgentsTreatment OutcomeCross-Over Studies

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research